said

Worldwide Olympic Partner TCL joins Olympic Museum Donors Wall

22 June 2025 - Worldwide Olympic Partner TCL has joined the Donors’ Wall at the Olympic Museum, with a commemorative stone unveiled during…

1 month ago

WhiteHawk Capital Partners Announces $70 Million Senior Secured Term Loan to a Leading Operator in the Food Distribution and Logistics Sector

 LOS ANGELES--(BUSINESS WIRE)--WhiteHawk Capital Partners: WhiteHawk Capital Partners has provided a $70 million senior secured term loan to an online…

1 month ago

MIPS and Cyient Semiconductor collaborate to bring Custom RISC-V-based intelligent power solutions to AI Power Delivery, Industrial Robotics, and Automotive

SAN JOSE, Calif. and HYDERABAD, India, June 12, 2025 /PRNewswire/ -- Cyient Semiconductors Private Limited, a fast-growing custom silicon company…

1 month ago

National Science Teaching Association Welcomes New Board and Leadership Council Members

MCLEAN, Va.--(BUSINESS WIRE)--#NSTA--The National Science Teaching Association (NSTA) today announced the newest members of its Board of Directors, as well…

2 months ago

European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy

MILAN, Italy, June 06, 2025 – Italfarmaco S.p.A. announced today that the European Commission (EC) has granted conditional marketing authorisation…

2 months ago

ServiceTitan Announces Fiscal First Quarter Financial Results

LOS ANGELES, June 05, 2025 (GLOBE NEWSWIRE) -- ServiceTitan (NASDAQ: TTAN), the software platform that powers the trades, today announced…

2 months ago

Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…

2 months ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of…

2 months ago

New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…

2 months ago